Our world-leading biologics technology platform & team provides a comprehensive service portfolio from conceptual to clinically proven biology. Harnessing innovative new technologies to further the envelop for biologics discovery.
We specialize in a variety of key bio-therapeutic areas, including oncology, cell biology, immunology, and inflammation. In order to work synergistically with our innovative Discovery programs, we’ve constructed a portfolio of innovative analysis tools to asses these novo compounds, as at the heart of each novo compound is a set of even more robust analysis tools.
Being able to fast-track development to clinical means having enough confidence about key attributes like DMPK and Toxicity, that is why we offer a bespoke set of studies meticulously tailored to provided the most precise DMPK and Toxicity analysis for each unique compound, as no two compounds are the same.
At the crux of each biologic therapeutic is a key protein or antibody. Our protein science team offers a selection of bespoke protein and antibody design and production services. Leveraging our MetaCHO platform technology we’re able to help our customers produce key proteins and antibodies faster and more economically.
Whether oncology, inflammation, or auto-immune, immunology plays a key role in determining the mechanism and systems that are vital to your drug development. We’ve created a portfolio of models and analysis tools to help you better understand these mechanisms.
In vitro biology may play a vital role in the preliminary screening of compounds, hence we understand the importance it plays to all our pharma and biotech clients in their future value creation. We’ve developed a portfolio of tools to help our clients better understand their compounds at an early stage to make those hard decisions easier.
The move to in-life is a big one and a pivotal point in determining the future of compounds. Our In Vivo platform has a vast selection of models and tools to help you make those pivotal decisions with clear and robust data.
Innovative modalities geared toward oncology are discovered and undertaken everyday, so we’ve constructed a portfolio of innovative analysis tools to asses these novo compounds, with a cell bank with over 900 cancer cell lines we’re well equipped to help you better understand your compound. As at the heart of each novo compound is a set of even more robust analysis tools.
At the crux of each biologic therapeutic is a key protein or antibody. Our protein science team offers a selection of bespoke protein and antibody design and production services. Leveraging our MetaCHO platform technology we’re able to help our customers produce key proteins and antibodies faster and more economically.
Whether oncology, inflammation, or auto-immune, immunology plays a key role in determining the mechanism and systems that are vital to your drug development. We’ve created a portfolio of models and analysis tools to help you better understand these mechanisms.
In vitro biology may play a vital role in the preliminary screening of compounds, hence we understand the importance it plays to all our pharma and biotech clients in their future value creation. We’ve developed a portfolio of tools to help our clients better understand their compounds at an early stage to make those hard decisions easier.
The move to in-life is a big one and a pivotal point in determining the future of compounds. Our In Vivo platform has a vast selection of models and tools to help you make those pivotal decisions with clear and robust data.
Innovative modalities geared toward oncology are discovered and undertaken everyday, so we’ve constructed a portfolio of innovative analysis tools to asses these novo compounds, with a cell bank with over 900 cancer cell lines we’re well equipped to help you better understand your compound. As at the heart of each novo compound is a set of even more robust analysis tools.
In the past decade we’ve seen the emergence of life changing drugs such as PD-1/PDL1 targeting antibodies, however many still lack the access to these life changing drugs due to supply shortages and high price points. we’ve developed a biosimilar development platform to fast track development and make PD1 drugs more accessible and cost effective for more patients globally.
At the crux of each biologic therapeutic is a key protein or antibody. In addition to bespoke antibody and protein production offered via Discovery Biologics, BioMetas also provides a large variety of off-the-shelf biological products from COVID-19, oncology focused, immunology focused antibodies, to Recombinant antibodies, and fusion proteins for your on demand needs.
In the past decade we’ve seen the emergence of life changing drugs such as PD-1/PDL1 targeting antibodies, however many still lack the access to these life changing drugs due to supply shortages and high price points. we’ve developed a biosimilar development platform to fast track development and make PD1 drugs more accessible and cost effective for more patients globally.
Contact Us
Headquarter
Address
334 Aidisheng Road, Pudong, Shanghai, China
info@biometasgroup.com
Telephone
(+86) 021-61050808
Contact Us
Headquarter
Address
334 Aidisheng Road, Pudong, Shanghai, China
info@biometasgroup.com
Telephone
(+86) 021-61050808
Research CRO Contract Research CDMO Biology Research studies Chem Partner Medicilon wuxi biologics wuxi apptech DMPK pharma-kinetics Druggability tox GLP tox Clinical KO mice mRNA antibody COVID-antibody mAb immunology cancer cell biology oncology fusion protein CRO services genescript probio pharmacology antibody discovery discovery biologics exploratory tox toxicity IND NDA BLA PD1 PDL1 ADC Antibody drug conjugate XDC CXO